Bayer HealthCare Unveils Advances in CT Contrast Dose Management™ Solutions

 Bayer HealthCare Unveils Advances in CT Contrast Dose Management™ Solutions

Powerful New Certegra® Informatics Workstation launched at SIIM 2012

Intended for U.S. Media Only

PR Newswire

TARRYTOWN, N.Y., June 7, 2012

TARRYTOWN, N.Y., June 7, 2012 /PRNewswire/ --Bayer Radiology & Interventional
announced the introduction of the Certegra® Workstation, an
informatics-driven, touch‐screen hub that enables time savings and improved
patient care through a powerful suite of CT Contrast Dose Management™
applications and a new P3T® 2.0 operating environment. The new Workstation
will be presented at the annual meeting of the Society for Imaging Informatics
in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial
launch in the U.S. and Canada, the Workstation will be rolled out in phases in
markets around the world.

The Workstation serves as a single interface for radiology technologists,
enabling them to provide improved patient care from study set-up and
preparation to administration of the patient's study. It will be the
cornerstone of Bayer's industry-first[1] Contrast Dose Management solution and
informatics platform. In establishing and uploading the patient's
contrast-injection record, the Workstation imports patient data directly from
the Modality Work List – reducing manual entry errors to the patient record.

"Today's technology-driven CT suite demands timely access to reliable
contrast-dose records throughout the chain of care," said Anthony Cinalli,
vice president of the informatics business at Bayer Radiology &
Interventional. "Enabling a single workflow-centralized interface, the
Workstation allows for fewer clicks, less manual entry and greater control
over the quality and consistency of patient care."

Interfacing with Medrad Stellant® CT injection systems, the Workstation's
comprehensive suite of software options provides physicians and healthcare
professionals instant access to real-time actionable CT contrast data captured
at the point of care ̶ enabling benefits including:

  oReduce sub-diagnostic studies, unnecessary rescans and associated
    radiation exposure[2] [3],(P3T 2.0 for personalized CT abdominal, cardiac
    and pulmonary angiography studies)
  oEnable more complete diagnostic decisions (PACS Outbound Interface)
  oSpeed-up radiology report turnaround time and create greater study-volume
    bandwidth (RIS and SR Outbound Interfaces)
  oImprove department performance by trending, reporting and analyzing
    actionable data with pinpoint accuracy (Informatics Starter Package, and
    the Data Analysis and Reporting Tool)

Bayer HealthCare will have the Certegra® Workstation on display at its booth
at SIIM 2012 (booth #217 - 221).

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the
world's leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec
31, 2011) and is represented in more than 100 countries. Find more information
at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com. The company assumes no liability
whatsoever to update these forward-looking statements or to conform  them to
future events or developments.

[1] Reference on file.

[2] Presented at Society of Thoracic Radiology (2008) Poster Session;
Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.

[3] 510(k) FDA clearance number: K082905

SOURCE Bayer HealthCare